|
IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB’s AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling. Further, says phase 1 trial of gallium maltolate for the treatment of patients with relapsed glioblastoma was initiated. This trial is nearing completion. Based on ‘encouraging’ preliminary signals of clinical response to GaM, a phase 2 clinical trial is warranted, company states. Current stock price: 1.92 pence, up 6.7% in London on Wednesday 12-month change: down 37% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
